Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Abroad (travel likely)RecruitingPHASE2

Conditions

ALK Gene Mutation · Lung Adenocarcinoma · Immunotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hunan Cancer Hospital, Changsha, Hunan, China
Contact: Study coordinator (Yongchang Zhang, MD) · zhangyongchang@csu.edu.cn · +86 731 89762323
Contact: Study coordinator (Nong Yang, MD) · yangnong0217@163.com · +86 731 89762321

Study leads

Yongchang C Zhang, MD
Principal Investigator
Hunan Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Alectinib Pharmacokinetic in Patients With NSCLC

Non-small Cell Lung Cancer Stage IIIB · ALK Gene Mutation

Abroad (travel likely)RecruitingPHASE1, PHASE2

Mexico City, Mexico

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Non Small Cell Lung Cancer · EGFR Gene Mutation · ALK Gene Mutation

Abroad (travel likely)RecruitingPHASE2

Changsha, China

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Non Small Cell Lung Cancer Metastatic · ALK Gene Mutation

Abroad (travel likely)RecruitingPHASE2

Aviano, Italy · Florence, Italy

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Non-Small Cell Carcinoma of Lung, TNM Stage 4 · Non-Small Cell Lung Cancer · EGFR Gene Mutation

Abroad (travel likely)Recruiting

Aurora, United States